RESUMO
One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients
No disponible
Assuntos
Humanos , Antineoplásicos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Cardiotoxicidade/diagnóstico , Protocolos Antineoplásicos , Diagnóstico Precoce , Fatores de Risco , Testes de Toxicidade/métodos , Padrões de Prática MédicaRESUMO
Chemotherapy and radiotherapy often result in reduced fertility in cancer patients. With increasing survival rates, fertility is an important quality-of-life concern for many young cancer patients. Around 70-75% of young cancer survivors are interested in parenthood but the numbers of patients who access fertility preservation techniques prior to treatment are significantly lower. Moreover, despite existing guidelines, healthcare professionals do not address fertility preservation issues adequately. There is a critical need for improvements in clinical care to ensure patients are well informed about infertility risks and fertility preservation options and to support them in their reproductive decision-making prior to cancer treatment (AU)
No disponible
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Preservação da Fertilidade/métodos , Preservação da Fertilidade/normas , Neoplasias/complicações , Neoplasias/prevenção & controle , Fatores de Risco , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/complicações , Saúde Reprodutiva/normas , Tratamentos com Preservação do Órgão/tendências , Gravidez/fisiologia , Preservação do Sêmen/tendênciasRESUMO
We report a case of primary CNS lymphoma treated with high-dose methotrexate in the first line. After disease progression the patient received cranial radiotherapy with concomitant temozolomide, followed by rituximab plus temozolomide, with complete remission of the disease maintained for at least two years and without major toxicity (AU)
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Anticorpos Monoclonais/administração & dosagem , Antineoplásicos/administração & dosagem , Neoplasias do Sistema Nervoso Central/tratamento farmacológico , Dacarbazina/análogos & derivados , Linfoma/tratamento farmacológico , Anticorpos Monoclonais Murinos , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Cérebro/patologia , Cérebro , Neoplasias do Sistema Nervoso Central/radioterapia , Dacarbazina/administração & dosagem , Dacarbazina/uso terapêutico , Irradiação Linfática/métodos , Imageamento por Ressonância Magnética/métodosRESUMO
We report the case of a 42 year-old woman with myasthenia gravis associated with a malignant thymoma. Despite surgery, chemotherapy and radiotherapy, the thymoma showed soft tissues, pleural and mediastinic progression. Unexpectedly, a complete remission of the thymoma was confirmed by FDG-PET after four cycles of immunoglobulins, administered as treatment for a myasthenic crisis. To our knowledge this is the first case report of complete remission of a malignant thymoma with immunoglobulin therapy (AU)
